You are viewing the site in preview mode

Skip to main content

As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

Featured Section: Cell, Tissue and Gene Therapy

The Cell, Tissue and Gene Therapy section aims to improve communication between basic and clinical research related to cell, tissue and gene therapies. Effective clinical therapies require efficient translation of research between the bench and bedside to allow the discovery, development, scale up, and production of cells, tissues and vectors. Edited by David Stroncek, the section considers submissions regarding the nature of cells, tissues and vectors used in clinical therapies; methods to collect, isolate and modify cells; and novel reagents, equipment, and instruments used in production. 


Read the latest articles in the Cell, Tissue and Gene Therapy section

Featured research: A circular RNA derived from PLXNB2 as a valuable predictor of the prognosis of patients with acute myeloid leukaemia

As a common haematological malignancy, acute myeloid leukaemia (AML), particularly with extramedullary infiltration (EMI), often results in a high mortality rate and poor prognosis. Circular RNAs (circRNAs) regulate biological and pathogenic processes, suggesting a potential role in AML. This study aims to find new prognostic and therapeutic targets potentially associated with AML.


The reported findings validate the high expression of circPLXNB2 and PLXNB2 in patients with AML. Elevated circPLXNB2 levels were associated with poor clinical outcomes in patients with AML. Importantly, circPLXNB2 accelerated tumour growth and progression, possibly by regulating PLXNB2 expression.

Featured review: Evaluation of exosome derivatives as bio-informational reprogramming therapy for cancer

Exosomes are nanoparticle sized extracellular vesicles (ECVs) that play important roles in cell-to-cell communication. Currently, exosomes are being explored for their potential as therapeutic agents for various degenerative diseases including cancer. The rationale behind their therapeutic ability is that they can transfer signaling biomolecules, and subsequently induce metabolic and physiological changes in diseased cells and tissues. 


Although exosomes were first believed to be a waste product of the cell, current research has demonstrated that these particles can serve as modulators of the immune system, act as cancer biomarkers, cause re-differentiation of cancer cells, and induce apoptosis in diseased cells. This review emphasizes the capabilities of specific subsets of extracellular vesicles that can potentially be used for cancer therapy, principally as a source of bi-informational reprogramming for malignant cells.

Journal of Translational Medicine has launched In Review, a new option that provides authors with on-demand information on the status of their manuscript, enables them to share their work with funders and their research community, and allows their colleagues to comment and collaborate - all whilst their manuscript is under review.

Read More

Meet the Editors

Get to know the Editors behind Journal of Translational Medicine! 

Articles

  1. Authors: Thomas E Ichim, Fabio Solano, Eduardo Glenn, Frank Morales, Leonard Smith, George Zabrecky and Neil H Riordan

    Content type: Review

Thank you to the JTRM reviewers!

Journal of Translational Medicine would like to warmly thank the top reviewers whose comments helped to shape the journal, for their assistance with review of manuscripts in Volume 18 (2020). 

Our companion journal

Translational Medicine Communications. the companion journal to Journal of Translational Medicine, is an interdisciplinary forum for all scientifically valid research from across translational medicine. 

The journal aims to improve transparency and reproducibility within translational medicine and considers research papers regardless of outcome or significance of findings.

Explore Translational Medicine Communications

New Section: Translational Megagenomics

We are excited to announce the addition of a new section to Journal of Translational Medicine entitled Transaltional Metagenomics. Led by Section Editor Souhaila Al Khodor, this exciting new section aims to fill the gap between basic research, translational medicine, and high-throughput data analysis for the human microbiome by providing innovative and novel scientific ideas.


The Translational Metagenomics section encompasses studies about the development and application of metagenomics, metatranscriptomics, microbial metabolomics or novel bioinformatics tools used to improve our knowledge on the microbiome. The section is especially interested in studies that go beyond description of the microbial composition and include experimental models used to support the proposed role of the microbiome in human health and diseases.

Editor-in-Chief: Francesco Marincola, Kite Pharma, USA

Dr. Marincola received his MD, summa cum laude from the University of Milan, Italy and Surgery training at Stanford University, California. His research interest lies in translational medicine and focuses on the development of strategies for the dynamic study of patients’ response to immunotherapy. His approach has brought seminal observations regarding the mechanisms leading to rejection of tumors, allograft rejection, graft-versus-host disease and autoimmunity.

Dr. Marincola is currently Global Head of Research at Kite Pharma, Santa Monica, California. He previously was President and Chief Scientific Officer at Refuge Biotechnologies, Menlo Park, California, Distinguished Research Fellow at AbbVie Corporation in Redwood City, California, Chief Research Officer at Sidra Medical and Research Center in Doha Qatar and Tenured Investigator at the National Institutes of Health, Bethesda Maryland. Dr. Marincola founded in 2003 the Journal of Translational Medicine of which he is currently the Editor-in-Chief. He is also Editor-in-Chief of Translational Medicine Communications. He is past-president of the Society for the Immunotherapy of Cancer (SITC) and of the International Society for Translational Medicine. Dr. Marincola is editor of several biomedical books including the SITC-affiliated Cancer Immunotherapy Principles and Practice Textbook. Dr. Marincola is an award winning fiction writer author of The Wise Men of Pizzo and the Cat Behind the Window.

Aims and scope

Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.

The journal covers all areas of translational medicine but also has several special sections:

Annual Journal Metrics

\